MX2023001301A - Uso antiviral de liraglutida y gefitinib. - Google Patents
Uso antiviral de liraglutida y gefitinib.Info
- Publication number
- MX2023001301A MX2023001301A MX2023001301A MX2023001301A MX2023001301A MX 2023001301 A MX2023001301 A MX 2023001301A MX 2023001301 A MX2023001301 A MX 2023001301A MX 2023001301 A MX2023001301 A MX 2023001301A MX 2023001301 A MX2023001301 A MX 2023001301A
- Authority
- MX
- Mexico
- Prior art keywords
- liraglutide
- gefitinib
- antiviral use
- antiviral
- coronavirus
- Prior art date
Links
- 239000005411 L01XE02 - Gefitinib Substances 0.000 title abstract 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title abstract 2
- 108010019598 Liraglutide Proteins 0.000 title abstract 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002584 gefitinib Drugs 0.000 title abstract 2
- 229960002701 liraglutide Drugs 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un preparado farmacéutico que comprende liraglutida o gefitinib o una sal, solvato o combinación de los mismos, en una cantidad eficaz para su uso en el tratamiento profiláctico o terapéutico de una enfermedad causada por una infección por un coronavirus o asociada a la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20188727 | 2020-07-30 | ||
| PCT/EP2021/071405 WO2022023533A2 (en) | 2020-07-30 | 2021-07-30 | Antiviral use of liraglutide and gefitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001301A true MX2023001301A (es) | 2023-03-14 |
Family
ID=71894735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001301A MX2023001301A (es) | 2020-07-30 | 2021-07-30 | Uso antiviral de liraglutida y gefitinib. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230270826A1 (es) |
| EP (1) | EP4188355A2 (es) |
| JP (1) | JP2023536591A (es) |
| KR (1) | KR20230047396A (es) |
| CN (1) | CN116322681A (es) |
| AU (1) | AU2021319014A1 (es) |
| BR (1) | BR112023001547A2 (es) |
| CA (1) | CA3190278A1 (es) |
| IL (1) | IL300204A (es) |
| MX (1) | MX2023001301A (es) |
| WO (1) | WO2022023533A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024017844A1 (en) * | 2022-07-18 | 2024-01-25 | Delta 4 Gmbh | Novel use of glucagon-like peptide 1 (glp-1) agonist |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105138862B (zh) * | 2015-07-31 | 2017-12-26 | 同济大学 | 一种协同抗癌症药物组合预测方法及药物组合物 |
| KR102456295B1 (ko) * | 2020-07-01 | 2022-10-19 | 한국화학연구원 | 상피세포 성장인자 수용체 억제제를 유효성분으로 포함하는 항바이러스용 조성물 |
-
2021
- 2021-07-30 EP EP21755918.6A patent/EP4188355A2/en active Pending
- 2021-07-30 CA CA3190278A patent/CA3190278A1/en active Pending
- 2021-07-30 KR KR1020237004967A patent/KR20230047396A/ko unknown
- 2021-07-30 US US18/017,847 patent/US20230270826A1/en active Pending
- 2021-07-30 CN CN202180064665.7A patent/CN116322681A/zh active Pending
- 2021-07-30 BR BR112023001547A patent/BR112023001547A2/pt unknown
- 2021-07-30 IL IL300204A patent/IL300204A/en unknown
- 2021-07-30 AU AU2021319014A patent/AU2021319014A1/en active Pending
- 2021-07-30 JP JP2023507260A patent/JP2023536591A/ja active Pending
- 2021-07-30 MX MX2023001301A patent/MX2023001301A/es unknown
- 2021-07-30 WO PCT/EP2021/071405 patent/WO2022023533A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023536591A (ja) | 2023-08-28 |
| BR112023001547A2 (pt) | 2023-04-11 |
| CN116322681A (zh) | 2023-06-23 |
| AU2021319014A1 (en) | 2023-02-23 |
| CA3190278A1 (en) | 2022-02-03 |
| EP4188355A2 (en) | 2023-06-07 |
| WO2022023533A3 (en) | 2022-04-14 |
| KR20230047396A (ko) | 2023-04-07 |
| IL300204A (en) | 2023-03-01 |
| WO2022023533A2 (en) | 2022-02-03 |
| US20230270826A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220200A1 (ar) | مركبات عالية النشاط ضد covid-19 | |
| MY196455A (en) | Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection | |
| PH12020551762A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| PH12017501421A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| ECSP12012106A (es) | Terapia antiviral | |
| MX2014005304A (es) | Biaril eter sulfonamidas y su uso como agentes terapeuticos. | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| MX2020010322A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
| EA201391108A1 (ru) | Лечение липодистрофии | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| EP4094774A4 (en) | USE OF INTERFERON IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF A CORONAVIRUS INFECTION OR THE PREVENTION OF A DISEASE CAUSED BY A CORONAVIRUS INFECTION | |
| MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
| MX2022014034A (es) | Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta. | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| MX2023001301A (es) | Uso antiviral de liraglutida y gefitinib. | |
| EA202190151A1 (ru) | Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеваниях | |
| MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
| MX2021011183A (es) | Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria. | |
| EA201891744A1 (ru) | ГЛЮКОНО-δ-ЛАКТОН ДЛЯ ЛЕЧЕНИЯ ВАГИНАЛЬНЫХ ГРИБКОВЫХ ИНФЕКЦИЙ | |
| WO2014193269A3 (ru) | Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций | |
| MX2023011297A (es) | Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6). |